Tamoxifen-related porphyria cutanea tarda
R Agarwal1, T J Peters, R C Coombes
1Section of Medicine, Institute of Cancer Research, Sutton, Surrey, United Kingdom. ragarwal@icr.ac.uk
Abstract:
We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.
More Related Videos
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
